Glioma stem cells and their roles within the hypoxic tumor microenvironment
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Tumor microenvironments are the result of cellular alterations in cancer that support unrestricted growth and proliferation and result in further modifications in cell behavior, which are critical for tumor progression. Angiogenesis and therapeutic resistance are known to be modulated by hypoxia and other tumor microenvironments, such as acidic stress, both of which are core features of the glioblastoma microenvironment. Hypoxia has also been shown to promote a stem-like state in both non-neoplastic and tumor cells. In glial tumors, glioma stem cells (GSCs) are central in tumor growth, angiogenesis, and therapeutic resistance, and further investigation of the interplay between tumor microenvironments and GSCs is critical to the search for better treatment options for glioblastoma. Accordingly, we summarize the impact of hypoxia and acidic stress on GSC signaling and biologic phenotypes, and potential methods to inhibit these pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
Kim, J., Kundu, M., Viollet, B., & Guan, K.-L. (2011) · Nature Cell Biology · doi:10.1038/ncb2152 · Cited by 7,227 · cited 1×
“Mammalian target of rapamycin (mTOR) is an intracellular kinase that regulates cell growth and cell cycle progression via signaling from nutrients and growth factors [220].”
BackgroundTargeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 2×
“pro-tumorigenic biology induced when blood vessel collapse occurs with anti-angiogenics [44, 204].”
BackgroundThe Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870 · cited 1×
“characterized these tumors as immunologically quiet and lymphocyte depleted, as the current understanding of immune activity in these tumors is that it is largely driven by monocytes and innate immunity [180].”
BackgroundSingle-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063 · cited 1×
“Of note, single cell RNA-sequencing has clearly determined that multiple subtypes exist within one GBM tumor [4, 15], suggesting that the vast heterogeneity within these tumors may complicate the ultimate goal of preventing recurrence of GBMs.”
BackgroundThe Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995 · cited 1×
“Mitogen-activated protein kinase (MAPK) can be activated by stress signaling such as that resulting from hypoxia [222].”
BackgroundA Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834 · cited 1×
“The VEGF antibody bevacizumab is already approved for treatment of GBM [92, 94-97], but bevacizumab is ineffective as a standalone therapy for newly diagnosed GBM patients [98, 99].”
BackgroundEMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545 · cited 1×
“Solid tumor cells in a hypoxic niche contribute to tumor aggressiveness and metastases, with specific roles for cancer stem cells that can have epithelial-tomesenchymal transition (EMT) phenotypes [121, 138].”
BackgroundHypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380 · cited 2×
“The beta subunit is constitutively expressed in all cells, while the alpha subunit exists in three isoforms, which are unstable and rapidly degraded in the presence of oxygen [40, 41].”
BackgroundA restricted cell population propagates glioblastoma growth after chemotherapy
Chen, J., Li, Y., Yu, T.-S., McKay, R. M., Burns, D. K., Kernie, S. G., & Parada, L. F. (2012) · Nature · doi:10.1038/nature11287 · Cited by 2,354
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells
Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., Shi, Q., Cao, Y., Lathia, J., McLendon, R. E., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.018 · Cited by 1,354 · cited 6×
“HIF1α and HIF2α in GSCs, whereas only HIF1α impacts VEGF levels in non-GSCs [50].”
BackgroundResultInfluentialSelf-citationZhou, W., Ke, S. Q., Huang, Z., Flavahan, W., Fang, X., Paul, J., Wu, L., Sloan, A. E., McLendon, R. E., Li, X., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3090 · Cited by 940 · cited 3×
“Periostin secretion levels positively correlated with TAM numbers and silencing periostin in GSCs resulted in decreased TAM density, decreased tumor growth, and increased survival of mice bearing GSC-derived xenografts [29].”
BackgroundGlioblastoma Stem Cells Generate Vascular Pericytes to Support Vessel Function and Tumor Growth
Cheng, L., Huang, Z., Zhou, W., Wu, Q., Donnola, S., Liu, J. K., Fang, X., Sloan, A. E., Mao, Y., Lathia, J. D., et al. (2013) · Cell · doi:10.1016/j.cell.2013.02.021 · Cited by 905
Heddleston, J. M., Li, Z., McLendon, R. E., Hjelmeland, A. B., & Rich, J. N. (2009) · Cell Cycle · doi:10.4161/cc.8.20.9701 · Cited by 813 · cited 14×
“Hypoxia and/or HIF signaling promote GSC maintenance GSCs are identified using cell surface markers or cell selection techniques that take advantage of phenotypes increased in this cellular subset, with sorting or validation using GSC markers that can include CD133, OCT4, and SOX2 among others [7, 9, 12, 13, 52, 56, 5…”
BackgroundInfluentialSelf-citationHIF-2α Promotes Hypoxic Cell Proliferation by Enhancing c-Myc Transcriptional Activity
Gordan, J. D., Bertout, J. A., Hu, C.-J., Diehl, J. A., & Simon, M. C. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.006 · Cited by 781
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis
Kaur, B., Khwaja, F. W., Severson, E. A., Matheny, S. L., Brat, D. J., & Van Meir, E. G. (2005) · Neuro-Oncology · doi:10.1215/s1152851704001115 · Cited by 725 · cited 1×
“The beta subunit is constitutively expressed in all cells, while the alpha subunit exists in three isoforms, which are unstable and rapidly degraded in the presence of oxygen [40, 41].”
BackgroundTargeting renal cell carcinoma with a HIF-2 antagonist
Chen, W., Hill, H., Christie, A., Kim, M. S., Holloman, E., Pavia-Jimenez, A., Homayoun, F., Ma, Y., Patel, N., Yell, P., et al. (2016) · Nature · doi:10.1038/nature19796 · Cited by 709
Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1α
Soeda, A., Park, M., Lee, D., Mintz, A., Androutsellis-Theotokis, A., McKay, R. D., Engh, J., Iwama, T., Kunisada, T., Kassam, A. B., et al. (2009) · Oncogene · doi:10.1038/onc.2009.252 · Cited by 656
Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance
Liau, B. B., Sievers, C., Donohue, L. K., Gillespie, S. M., Flavahan, W. A., Miller, T. E., Venteicher, A. S., Hebert, C. H., Carey, C. D., Rodig, S. J., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2016.11.003 · Cited by 535
Hypoxia Induces Production of L-2-Hydroxyglutarate
Intlekofer, A. M., Dematteo, R. G., Venneti, S., Finley, L. W. S., Lu, C., Judkins, A. R., Rustenburg, A. S., Grinaway, P. B., Chodera, J. D., Cross, J. R., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.06.023 · Cited by 513
Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours
Garcia-Bermudez, J., Baudrier, L., La, K., Zhu, X. G., Fidelin, J., Sviderskiy, V. O., Papagiannakopoulos, T., Molina, H., Snuderl, M., Lewis, C. A., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0118-z · Cited by 442
Bar, E. E., Lin, A., Mahairaki, V., Matsui, W., & Eberhart, C. G. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.091021 · Cited by 373
Hypoxia‐inducible factors in regulation of immune responses in tumour microenvironment
Kumar, V., & Gabrilovich, D. I. (2014) · Immunology · doi:10.1111/imm.12380 · Cited by 329
L-2-Hydroxyglutarate production arises from noncanonical enzyme function at acidic pH
Intlekofer, A. M., Wang, B., Liu, H., Shah, H., Carmona-Fontaine, C., Rustenburg, A. S., Salah, S., Gunner, M. R., Chodera, J. D., Cross, J. R., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2307 · Cited by 268
McIntyre, A., Patiar, S., Wigfield, S., Li, J.-L., Ledaki, I., Turley, H., Leek, R., Snell, C., Gatter, K., Sly, W. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1877 · Cited by 239
Kolenda, J., Jensen, S. S., Aaberg-Jessen, C., Christensen, K., Andersen, C., Brünner, N., & Kristensen, B. W. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0357-8 · Cited by 144 · cited 15×
“Hypoxia and/or HIF signaling promote GSC maintenance GSCs are identified using cell surface markers or cell selection techniques that take advantage of phenotypes increased in this cellular subset, with sorting or validation using GSC markers that can include CD133, OCT4, and SOX2 among others [7, 9, 12, 13, 52, 56, 5…”
BackgroundInfluentialHicks, K. O., Siim, B. G., Jaiswal, J. K., Pruijn, F. B., Fraser, A. M., Patel, R., Hogg, A., Liyanage, H. D. S., Dorie, M. J., Brown, J. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1439 · Cited by 132
Johansson, E., Grassi, E. S., Pantazopoulou, V., Tong, B., Lindgren, D., Berg, T. J., Pietras, E. J., Axelson, H., & Pietras, A. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.049 · Cited by 121 · cited 1×
“intracellular domain that interacts with HIF2α and promotes HIF dependent hypoxic signaling [76].”
BackgroundSullivan, R., & Graham, C. H. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1090 · Cited by 65
Wang, P., Lan, C., Xiong, S., Zhao, X., Shan, Y., Hu, R., Wan, W., Yu, S., Liao, B., Li, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15888 · Cited by 48
Cited by
Iron Metabolism: State of the Art in Hypoxic Cancer Cell Biology
Liu, S., Cao, X., Wang, D., & Zhu, H. (2022) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2022.109199 · Cited by 31
Amin, W., Enam, S. A., Sufiyan, S., Ghias, K., Bajwa, M. H., Ilyas, S., Laghari, A. A., Naeem, S., Abidi, S. H., & Mughal, N. (2024) · PLOS ONE · doi:10.1371/journal.pone.0311308 · Cited by 8
“Considering the slower growth rate of low-grade gliomas compared to high-grade ones, it is reasonable to infer that nutrient stress is more pronounced in high-grade gliomas [40].”
Background
Metadata
- Authors
- Boyd, N. H., Tran, A. N., Bernstock, J. D., Etminan, T., Jones, A. B., Gillespie, G. Y., Friedman, G. K., & Hjelmeland, A. B.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2021
- Volume
- 11
- Issue
- 2
- Pages
- 665-683
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W3097646670
- Cited by
- 221
- References
- 32
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.